Quick Answer
Inhibikase Therapeutics, Inc. reported R&D Expense of $29.79 million for fiscal year 2025.
Inhibikase Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $29.79M | +73.1% |
| 2024 | $17.21M | +26.4% |
| 2023 | $13.62M | +13.2% |
| 2022 | $12.03M | +6.0% |
| 2021 | $11.36M | +1170.9% |
| 2020 | $893.8K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.65M | +82.6% | +45.1% |
| June 30, 2025 | $5.27M | +71.4% | -49.9% |
| March 31, 2025 | $10.51M | +282.1% | +150.9% |
| September 30, 2024 | $4.19M | +29.9% | +36.2% |
| June 30, 2024 | $3.08M | -32.2% | +11.8% |
| March 31, 2024 | $2.75M | -3.6% | -14.7% |
| September 30, 2023 | $3.23M | +8.2% | -28.9% |
| June 30, 2023 | $4.54M | +52.1% | +58.9% |
- Inhibikase Therapeutics, Inc. showed an increase of +73.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Inhibikase Therapeutics, Inc.’s r&d expense has grown by 3233.3% (from $893.8 thousand to $29.79 million).
- The most recent figure is from Inhibikase Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: